207 related articles for article (PubMed ID: 25792707)
21. Celecoxib: new indication. Colorectal cancer: no preventive benefit.
Prescrire Int; 2006 Feb; 15(81):13-5. PubMed ID: 16548099
[TBL] [Abstract][Full Text] [Related]
22. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis.
Samadder NJ; Foster N; McMurray RP; Burke CA; Stoffel E; Kanth P; Das R; Cruz-Correa M; Vilar E; Mankaney G; Buttar N; Thirumurthi S; Turgeon DK; Sossenheimer M; Westover M; Richmond E; Umar A; Della'Zanna G; Rodriguez LM; Szabo E; Zahrieh D; Limburg PJ
Gut; 2023 Feb; 72(2):256-263. PubMed ID: 35636921
[TBL] [Abstract][Full Text] [Related]
23. Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.
Kraus S; Hummler S; Toriola AT; Poole EM; Scherer D; Kotzmann J; Makar KW; Kazanov D; Galazan L; Naumov I; Coghill AE; Duggan D; Gigic B; Arber N; Ulrich CM
Pharmacogenet Genomics; 2013 Aug; 23(8):428-437. PubMed ID: 23778325
[TBL] [Abstract][Full Text] [Related]
24. Celecoxib for the prevention of sporadic colorectal adenomas.
Bertagnolli MM; Eagle CJ; Zauber AG; Redston M; Solomon SD; Kim K; Tang J; Rosenstein RB; Wittes J; Corle D; Hess TM; Woloj GM; Boisserie F; Anderson WF; Viner JL; Bagheri D; Burn J; Chung DC; Dewar T; Foley TR; Hoffman N; Macrae F; Pruitt RE; Saltzman JR; Salzberg B; Sylwestrowicz T; Gordon GB; Hawk ET;
N Engl J Med; 2006 Aug; 355(9):873-84. PubMed ID: 16943400
[TBL] [Abstract][Full Text] [Related]
25. Cutaneous Application of Celecoxib for Inflammatory and Cancer Diseases.
Quiñones OG; Pierre MBR
Curr Cancer Drug Targets; 2019; 19(1):5-16. PubMed ID: 29714143
[TBL] [Abstract][Full Text] [Related]
26. In Vitro and In Vivo Evaluation of DMSO and Azone as Penetration Enhancers for Cutaneous Application of Celecoxib.
Senna TD; Mata Dos Santos HA; Kibwila DM; Leitao AC; Santos Pyrrho AD; de Padula M; Rosas EC; Padua TA; Lara MG; Riemma Pierre MB
Curr Drug Deliv; 2017; 14(7):992-1004. PubMed ID: 28124617
[TBL] [Abstract][Full Text] [Related]
27. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
[TBL] [Abstract][Full Text] [Related]
28. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
[TBL] [Abstract][Full Text] [Related]
29. Chemopreventive efficacy of combined piroxicam and difluoromethylornithine treatment of Apc mutant Min mouse adenomas, and selective toxicity against Apc mutant embryos.
Jacoby RF; Cole CE; Tutsch K; Newton MA; Kelloff G; Hawk ET; Lubet RA
Cancer Res; 2000 Apr; 60(7):1864-70. PubMed ID: 10766173
[TBL] [Abstract][Full Text] [Related]
30. Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Lin BS; Madson N; McLaren CE; Gerner EW; Meyskens FL
Cancer Causes Control; 2012 Oct; 23(10):1739-44. PubMed ID: 22907422
[TBL] [Abstract][Full Text] [Related]
31. Colorectal cancer prevention: is an ounce of prevention worth a pound of cure?
Gill S; Sinicrope FA
Semin Oncol; 2005 Feb; 32(1):24-34. PubMed ID: 15726503
[TBL] [Abstract][Full Text] [Related]
32. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial.
Meyskens FL; McLaren CE; Pelot D; Fujikawa-Brooks S; Carpenter PM; Hawk E; Kelloff G; Lawson MJ; Kidao J; McCracken J; Albers CG; Ahnen DJ; Turgeon DK; Goldschmid S; Lance P; Hagedorn CH; Gillen DL; Gerner EW
Cancer Prev Res (Phila); 2008 Jun; 1(1):32-8. PubMed ID: 18841250
[TBL] [Abstract][Full Text] [Related]
33. Celecoxib for the Prevention of Colorectal Adenomas: Results of a Suspended Randomized Controlled Trial.
Thompson PA; Ashbeck EL; Roe DJ; Fales L; Buckmeier J; Wang F; Bhattacharyya A; Hsu CH; Chow SH; Ahnen DJ; Boland CR; Heigh RI; Fay DE; Hamilton SR; Jacobs ET; Martinez EM; Alberts DS; Lance P
J Natl Cancer Inst; 2016 Dec; 108(12):. PubMed ID: 27530656
[TBL] [Abstract][Full Text] [Related]
34. Celecoxib use and circulating oxylipins in a colon polyp prevention trial.
Martinez JA; Yang J; Wertheim BC; Roe DJ; Schriewer A; Lance P; Alberts DS; Hammock BD; Thompson PA
PLoS One; 2018; 13(4):e0196398. PubMed ID: 29698447
[TBL] [Abstract][Full Text] [Related]
35. Children's International Polyposis (CHIP) study: a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis.
Burke CA; Phillips R; Berger MF; Li C; Essex MN; Iorga D; Lynch PM
Clin Exp Gastroenterol; 2017; 10():177-185. PubMed ID: 28765715
[TBL] [Abstract][Full Text] [Related]
36. Celecoxib Colorectal Bioavailability and Chemopreventive Response in Patients with Familial Adenomatous Polyposis.
Yang P; Zuo X; Advani S; Wei B; Malek J; Day RS; Shureiqi I
Cancer Prev Res (Phila); 2022 Apr; 15(4):217-223. PubMed ID: 34610992
[TBL] [Abstract][Full Text] [Related]
37. Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.
Zell JA; Pelot D; Chen WP; McLaren CE; Gerner EW; Meyskens FL
Cancer Prev Res (Phila); 2009 Mar; 2(3):209-12. PubMed ID: 19258540
[TBL] [Abstract][Full Text] [Related]
38. A randomized, placebo-controlled, preoperative trial of allopurinol in subjects with colorectal adenoma.
Puntoni M; Branchi D; Argusti A; Zanardi S; Crosta C; Meroni E; Munizzi F; Michetti P; Coccia G; De Roberto G; Bandelloni R; Turbino L; Minetti E; Mori M; Salvi S; Boccardo S; Gatteschi B; Benelli R; Sonzogni A; DeCensi A
Cancer Prev Res (Phila); 2013 Feb; 6(2):74-81. PubMed ID: 23213070
[TBL] [Abstract][Full Text] [Related]
39. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug with D,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet.
Reddy BS; Nayini J; Tokumo K; Rigotty J; Zang E; Kelloff G
Cancer Res; 1990 May; 50(9):2562-8. PubMed ID: 2109653
[TBL] [Abstract][Full Text] [Related]
40. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial.
Chan FK; Lanas A; Scheiman J; Berger MF; Nguyen H; Goldstein JL
Lancet; 2010 Jul; 376(9736):173-9. PubMed ID: 20638563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
